Immutep AIPAC Phase IIb Eftilagimod Alpha Metastatic Breast Cancer Trial Results

Final results from the randomized AIPAC phase IIb trial evaluating eftilagimod alpha (soluble LAG-3 protein) combined with weekly paclitaxel in hormone receptor-positive, HER2-negative metastatic breast cancer patients. The study showed a non-significant 2.9-month median overall survival increase overall, with clinically meaningful improvements in specific subgroups including patients under 65 years, those with low baseline monocytes, and luminal B disease.